Overweight
Conditions
Keywords
Kochujang,, visceral fat, population
Brief summary
With the epidemic of obesity and diabetes growing around the world, Kochujang (KCJ) may be potentially effective in preventing and treating obesity and cardiovascular risks if proven in humans. However, human trial still have not been reported with KCJ supplementation. In the present study, we investigated the hypothesis that KCJ supplementation can be decrease the body fat and improve blood lipid profiles in overweight adults.
Detailed description
The aim of this study was to evaluate the efficacy of KCJ supplementation on anthropometric parameters, visceral fat/subcutaneous fat, and blood lipid profiles in overweight subjects. Sixty overweight subjects with BMI \>25 kg/m2 and waist-hip-ratio (WHR) ≥ 0.90 for men and ≥ 0.85 for women were randomly assigned to either KCJ supplement (n=30, 32 g/day) or placebo (n=30, 32 g/day) group for 12 weeks.
Interventions
DIETARY_SUPPLEMENTKochujang
Kochujang (32g/day) for 12weeks.
DIETARY_SUPPLEMENTplacebo
placebo(32g/day) for 12weeks
Sponsors
Chonbuk National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* BMI \>25kg/m2 and 2)Waist-Hip Ratio (WHR): WHR\> 0.90(male), WHR\>0.85(female)
Exclusion criteria
* lipid metabolic disorders * \>10% changes in body weight in the past 3 months * Cardiovascular disease such as arrhythmia, heart failure, myocardial infarction, and wearing pacemaker * Allergy or hypersensitivity to any of the ingredients in the test products - History of reaction to any of the experimental products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery * Participation in other clinical trials within the past 2 months * Abnormal hepatic liver function, renal disease such as acute * chronic renal failure, nephrotic syndrome * Use of anti-psychosis drug therapy within 2 months * Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * History of alcohol or substance abuse * Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visceral fat | after 12 weeks of consumption |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index | after 12 weeks of consumption |
| Subcutaneous fat | after 12weeks |
| Triglyceride | after 12week of consumption |
| Atherosclerosis index | after 12weeks of consumption |
| Apolipoprotein | after 12weeks of consumption |
Outcome results
None listed